1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,893 | 0,973 | 22.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08. | Earnings Call: Nanoform reduziert Cash-Burn in Q2 2026 und erzielt regulatorische Fortschritte | - | Investing.com Deutsch | ||
| 20.08. | Nanoform Q2 2026 slides: cash burn drops 57% as GMP projects rise | 1 | Investing.com | ||
| 20.08. | Nanoform Finland Oyj Q2 Loss Declines | 2 | RTTNews | ||
| 20.08. | Nanoform steigert Umsatz um 16 % und verringert Quartalsverlust | 2 | Investing.com Deutsch | ||
| 20.08. | Nanoform Finland Oyj: Nanoform Q2 2026 - Positive feedback from scientific advice meeting in the UK, significantly improved cash flow and discussions with CDMOs on sterile GMP for our Biologics technology initiated | 432 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | August 20, 2026 at 08:10:00 EEST
Nanoenzalutamide project continues with the communicated multitrack strategy supported by all partners. After a positive scientific... ► Artikel lesen | |
| 05.08. | Nanoform Finland Oyj: Inside information: Positive Feedback from UK MHRA Scientific Advice Meeting regarding Nanoenzalutamide | 388 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | August 05, 2026 at 12:00:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, announced today that it... ► Artikel lesen | |
| 19.05. | Nanoform Finland Oyj: Nanoform Q1 2026 report - Record first quarter revenue, income and gross margin, first exclusivity deal signed around our Biologics technology | 907 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | May 19, 2026 at 08:10:00 EEST
Record first quarter revenue, income and gross margin. Revenue grew by 45%, gross margin reached 94% and operating costs fell by... ► Artikel lesen | |
| NANOFORM FINLAND Aktie jetzt für 0€ handeln | |||||
| 12.05. | Nanoform Finland Oyj: Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High Concentration Subcutaneous Delivery | 800 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | May 12, 2026 at 08:00:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has... ► Artikel lesen | |
| 21.04. | Nanoform Finland Oyj: Resolutions of Nanoform Finland Plc's Annual General Meeting on April 21, 2026 | 630 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | April 21, 2026 at 12:20:00 EEST
Nanoform Finland Plc (the "Company" or "Nanoform") held its Annual General Meeting for 2026 on April 21, 2026 at the Company's... ► Artikel lesen | |
| 02.03. | Nanoform Finland Oyj: The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees | 966 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | March 02, 2026 at 08:10:00 EET
Helsinki, Finland - The Annual General Meeting of Nanoform Finland Plc ("Nanoform") has on 15 April 2025 authorized the company's... ► Artikel lesen | |
| 26.02. | Nanoform Finland Oyj: Nanoform Q4 & FY2025 report - Next: the submission of a marketing authorization application for Nanoenzalutamide in Europe | 876 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | February 26, 2026 at 08:10:00 EET
Product kernel strategy continues to gain traction. Nanoenzalutamide: pivotal human fed and fasted study concluded, three more... ► Artikel lesen | |
| 07.01. | Nanoform Finland Oyj: Inside information: Nanoform starts change negotiations as part of announced new midterm business targets for 2030 | 873 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | January 07, 2026 at 08:05:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform") starts change negotiations in accordance with the Act on Cooperation.... ► Artikel lesen | |
| 16.12.25 | Nanoform Finland Oyj: Inside information: Nanoform announces new midterm business targets for 2030 | 1.717 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | December 16, 2025 at 07:00:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced new midterm... ► Artikel lesen | |
| 12.11.25 | Nanoform Finland Oyj: Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set | 1.929 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | November 12, 2025 at 08:10:00 EET
Our product kernels see good momentum. Nanoenzalutamide progresses with the fed arm of the pivotal human study. Licensing and... ► Artikel lesen | |
| 11.11.25 | Nanoform Finland Oyj: Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License | 1.098 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | November 11, 2025 at 08:00:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that... ► Artikel lesen | |
| 27.10.25 | Nanoform Finland Oyj: Nanoform Partners With Revio Therapeutics To Develop Long-Acting Locally-Delivered Hydrogel Nanoformulation To Treat Glioma | 1.058 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | October 27, 2025 at 09:10:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced a partnership... ► Artikel lesen | |
| 14.10.25 | Nanoform Finland Oyj: Nanoform Outlicenses Nanoencorafenib And Signs Development And Commercialisation Agreement With A.forall And IMGA | 1.074 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | October 14, 2025 at 09:30:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has... ► Artikel lesen | |
| 30.09.25 | Nanoform Finland Oyj: Nanoform Expands Commercial Presence In Asia With A&ls Pharma In South Korea | 1.113 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | September 30, 2025 at 09:30:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced it has entered... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 19,800 | -0,40 % | EQS-News: Formycon AG: Formycon setzt Maßstäbe in der Biosimilar-Entwicklung: Wissenschaftliche Grundlagen des innovativen Entwicklungsprogramms für FYB206 im Fachjournal BioDrugs veröffentlicht | EQS-News: Formycon AG
/ Schlagwort(e): Wissenschaftl. Publikation
Formycon setzt Maßstäbe in der Biosimilar-Entwicklung: Wissenschaftliche Grundlagen des innovativen Entwicklungsprogramms... ► Artikel lesen | |
| NVE | 92,00 | -2,65 % | NVE Q1 2027 Earnings Call: Complete Transcript | ||
| RIBER | 9,320 | 0,00 % | RIBER: FIRST-HALF 2026 BUSINESS ACTIVITY Business growth, resilient order book and continued rollout of ROSIE | FIRST-HALF 2026 BUSINESS ACTIVITYBusiness growth, resilient order book and continued rollout of ROSIE Bezons, July 22, 2026 - 8:00 am - RIBER, the global leader in molecular beam epitaxy (MBE) equipment... ► Artikel lesen | |
| GAUZY | 6,600 | +2,96 % | GAUZY LTD: Gauzy Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal | TEL AVIV, Israel, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (Nasdaq: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced receipt of a delisting... ► Artikel lesen | |
| ONTO INNOVATION | 245,10 | -1,13 % | $1000 Invested In Onto Innovation 10 Years Ago Would Be Worth This Much Today | ||
| GOMSPACE | 0,972 | -0,72 % | GomSpace A/S: GomSpace signs 3.8 MEUR multi-phased partnership agreement with European space company specializing in advanced systems and critical technology | The initial agreement establishes a new customer relationship and framework for long-term cooperation.STOCKHOLM, Sept. 18, 2026 /PRNewswire/ -- GomSpace has signed a multi-phased partnership agreement... ► Artikel lesen | |
| KOPIN | 4,101 | -5,27 % | Fabric.AI Appoints Haynes Boone as Counsel to Support Joint Intellectual Property with Kopin | ||
| LAMPETIA | 0,157 | 0,00 % | EQS-Adhoc: Lampetia AG: Einigung über die Beendigung von Rechtsstreitigkeiten | EQS-Ad-hoc: Lampetia AG / Schlagwort(e): Sonstiges
Lampetia AG: Einigung über die Beendigung von Rechtsstreitigkeiten
16.07.2026 / 22:00 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| NANOVIRICIDES | 1,470 | +9,70 % | NanoViricides, Inc.: Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides | SHELTON, CT / ACCESS Newswire / September 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces... ► Artikel lesen | |
| SOLESENCE | 0,805 | -0,12 % | Solésence, Inc.: Solésence Reports Second Quarter 2026 Financial Results | Quarterly Report Filed on Form 10-Q Company to Host Conference Call at 5:00 p.m. ET Today ROMEOVILLE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically... ► Artikel lesen | |
| ACACIA RESEARCH | 3,720 | -3,63 % | ACACIA RESEARCH CORP - 10-Q, Quarterly Report | ||
| ADVANCE ZINCTEK | 0,346 | 0,00 % | Advance Zinctek Ltd Profit Advances In Full Year | ||
| ANTEOTECH | 0,003 | -11,76 % | ANTEOTECH LTD: FY26 Results Investor Webinar | ||
| REGION GROUP | 1,345 | -0,43 % | REGION GROUP: 2026 Notice of Annual General Meeting | ||
| XTPL | 17,480 | +2,94 % | EQS-News: XTPL S.A.: XTPL is in the process of securing a strategic investor from Taiwan to strengthen its position in the semiconductor market | Issuer: XTPL S.A.
/ Key word(s): Capital Increase/Agreement
XTPL is in the process of securing a strategic investor from Taiwan to strengthen its position in the semiconductor... ► Artikel lesen |
Das Unternehmen NANOFORM FINLAND OYJ kann der Branche Nanotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,911 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOFORM FINLAND OYJ finden Sie auf Wallstreet Online.